Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of four antiviral medications that have been studied for potential interactions. Telaprevir is an NS3/4A protease inhibitor used for treating chronic Hepatitis C virus (HCV) genotype 1 infection. Darunavir, ritonavir, and fosamprenavir are HIV protease inhibitors used in antiretroviral therapy for HIV infection. Studies have shown significant drug interactions between these medications, with ritonavir-boosted darunavir and fosamprenavir reducing telaprevir concentrations, and telaprevir reducing darunavir and fosamprenavir levels. Due to these bidirectional interactions, co-administration is not recommended.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on telaprevir + darunavir + ritonavir + fosamprenavir.